A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.

Trial Details

NCT ID
NCT07030907
Phase
PHASE1
Sponsor
Outpace Bio, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • OPB-101
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Buffalo, New York, United States|42.88645,-78.87837
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age ≥ 18 years of age at the time of signing the informed consent form.
  • Histologically confirmed diagnosis of high grade serous epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological f…
  • Recurrent platinum-resistant disease defined as: Disease that has recurred within 6 months of the last receipt of platinum-based therapy.
  • Received at least 2 prior lines of systemic chemotherapy including a platinum-based chemotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →